Anne Halpin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anne Halpin has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Lori J. West
University of Alberta
7 shared publications - Simon Urschel
Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
4 shared publications - Bruce Motyka
Department of Pediatrics, University of Alberta, Edmonton, AB, Canada
3 shared publications - Cathi Murphey
Immunogenetics Lab at Southwest Immunodiagnostics, Inc., San Antonio, TX
2 shared publications - Maria Ellis
Department of Pediatrics, University of Alberta, Edmonton, AB, Canada
2 shared publications - Michael Khoury
Department of Pediatrics University of Alberta Edmonton Alberta Canada
2 shared publications
Latest Publications
- 18 March 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (7) , 1103-1107
Advancing ABO-histocompatibility: Impact of multiplexed ABO antibody immunoassay to increase precision in pediatric heart transplantation
- 18 March 2026
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (7) , 1103-1107
Advancing ABO-histocompatibility: Impact of multiplexed ABO antibody immunoassay to increase precision in pediatric heart transplantation
- Open Access
Evaluation of Multiplexed Liquid Glycan Array (LiGA) for Serological Detection of Glycan-binding Antibodies
We test the performance of the multiplexed liquid glycan array (LiGA) technology in serological assays. Specifically, we use LiGA to detect ABO blood group antibodies in human serum. This LiGA, which we name ABO-LiGA, contains ABO blood group trisaccharide glycans with an ethylazido aglycone conjugated to groups of ten multi-barcoded M13 particles carrying dibenzocyclooctyne (DBCO) on p8 proteins. ELISA clonal binding assays to anti-A/B antibodies confirmed the functional performance of ABO-clones and aligned with next-generation sequencing (NGS) of the mixed clones. Multiple DNA-barcoded technical replicates in LiGA allow for quantification of reproducibility and robustness as determined by the Z’-score using NGS. We then tested ABO-LiGA for specific detection of IgG and IgM anti-A and anti-B IgG and IgM antibodies in human serum samples. Comparison of antibody binding responses in sera from 31 healthy donors to ABO-LiGA with an ABO-Luminex-based method revealed consistent responses to LiGA-ABO but also minor deficiencies of ABO-LiGA such as low robustness of the current assay format and a limited ability to detect low intensity antibody responses. Some results point to undesired interactions of serum antibodies with small-footprint glycans conjugated to phage via the bulky DBCO moiety. This report illuminates the path for future development of LiGA-based serological assays and suggests the need to develop alternative methods for conjugating glycans to phage to avoid liabilities of the hydrophobic DBCO moiety.
Open AccessEvaluation of Multiplexed Liquid Glycan Array (LiGA) for Serological Detection of Glycan-binding Antibodies
We test the performance of the multiplexed liquid glycan array (LiGA) technology in serological assays. Specifically, we use LiGA to detect ABO blood group antibodies in human serum. This LiGA, which we name ABO-LiGA, contains ABO blood group trisaccharide glycans with an ethylazido aglycone conjugated to groups of ten multi-barcoded M13 particles carrying dibenzocyclooctyne (DBCO) on p8 proteins. ELISA clonal binding assays to anti-A/B antibodies confirmed the functional performance of ABO-clones and aligned with next-generation sequencing (NGS) of the mixed clones. Multiple DNA-barcoded technical replicates in LiGA allow for quantification of reproducibility and robustness as determined by the Z’-score using NGS. We then tested ABO-LiGA for specific detection of IgG and IgM anti-A and anti-B IgG and IgM antibodies in human serum samples. Comparison of antibody binding responses in sera from 31 healthy donors to ABO-LiGA with an ABO-Luminex-based method revealed consistent responses to LiGA-ABO but also minor deficiencies of ABO-LiGA such as low robustness of the current assay format and a limited ability to detect low intensity antibody responses. Some results point to undesired interactions of serum antibodies with small-footprint glycans conjugated to phage via the bulky DBCO moiety. This report illuminates the path for future development of LiGA-based serological assays and suggests the need to develop alternative methods for conjugating glycans to phage to avoid liabilities of the hydrophobic DBCO moiety.
- Open Access
- 10 April 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (9) , 1884-1894
Multiplex bead immunoassay in ABO-A2-incompatible kidney transplantation
- 10 April 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (9) , 1884-1894
Open AccessMultiplex bead immunoassay in ABO-A2-incompatible kidney transplantation
- Open Access
- 12 December 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 67, 102333
Islet transplantation outcomes in type 1 diabetes and transplantation of HLA-DQ8/DR4: results of a single-centre retrospective cohort in Canada
- 12 December 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 67, 102333
Open AccessIslet transplantation outcomes in type 1 diabetes and transplantation of HLA-DQ8/DR4: results of a single-centre retrospective cohort in Canada
- Open Access
- 3 January 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (3) , e14459
Successful ABO incompatible heart transplantation after desensitization therapy in an older child
Background: ABO‐incompatible heart transplantation (HTx) has become a standard procedure for children below 2 years of age due to an immunologically immature immune system and associated low isohemagglutinin titers.Methods: We report a case of an ABO‐incompatible HTx (recipient blood group O, donor blood group A) at the age of 5 years and 11 months with a fully matured immune system and previously high isohemagglutinin titers that diminished as a result of human leucocyte antigen (HLA) desensitization therapy with rituximab and immunoglobulins.Results: The anti‐A titer at the time of HTx was 1:16 with post‐transplant isoagglutinin titers never exceeding 1:4 without any signs of rejection with now 3 years of post‐HTx follow‐up.Conclusions: ABO isohemagglutinin titers should be routinely assessed in children undergoing desensitization therapy since ABOi transplantation can be considered in selected cases to expand the donor pool with the option of crossing the ABO barrier to find a better‐matched allograft.
- 3 January 2023
- Published by Wiley in Pediatric Transplantation
- Vol. 27 (3) , e14459
Open AccessSuccessful ABO incompatible heart transplantation after desensitization therapy in an older child
Background: ABO‐incompatible heart transplantation (HTx) has become a standard procedure for children below 2 years of age due to an immunologically immature immune system and associated low isohemagglutinin titers.Methods: We report a case of an ABO‐incompatible HTx (recipient blood group O, donor blood group A) at the age of 5 years and 11 months with a fully matured immune system and previously high isohemagglutinin titers that diminished as a result of human leucocyte antigen (HLA) desensitization therapy with rituximab and immunoglobulins.Results: The anti‐A titer at the time of HTx was 1:16 with post‐transplant isoagglutinin titers never exceeding 1:4 without any signs of rejection with now 3 years of post‐HTx follow‐up.Conclusions: ABO isohemagglutinin titers should be routinely assessed in children undergoing desensitization therapy since ABOi transplantation can be considered in selected cases to expand the donor pool with the option of crossing the ABO barrier to find a better‐matched allograft.
- Open Access
- 30 December 2021
- Published by Taylor & Francis in Virulence
- Vol. 13 (1) , 30-45
ABO blood group is involved in the quality of the specific immune response anti-SARS-CoV-2
Since December 2019, the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread throughout the world. To eradicate it, it is crucial to acquire a strong and long-lasting anti-SARS-CoV-2 immunity, by either natural infection or vaccination. We collected blood samples 12–305 days after positive polymerase chain reactions (PCRs) from 35 recovered individuals infected by SARS-CoV-2. Peripheral blood mononuclear cells were stimulated with SARS-CoV-2-derived peptide pools, such as the spike (S), nucleocapsid (N) and membrane (M) proteins, and we quantified anti-S immunoglobulins in plasma. After 10 months post-infection, we observed a sustained SARS-CoV-2-specific CD4+ T-cell response directed against M-protein, but responses against S- or N-proteins were lost over time. Besides, we demonstrated that O-group individuals presented significantly lower frequencies of specific CD4+ T-cell responses against Pep-M than non O-group individuals. The non O-group subjects also needed longer to clear the virus, and they lost cellular immune responses over time, compared to the O-group individuals, who showed a persistent specific immune response against SARS-CoV-2. Therefore, the S-specific immune response was lost over time, and individual factors might determine the sustainability of the body’s defenses, which must be considered in the future design of vaccines to achieve continuous anti-SARS-CoV-2 immunity.
- 30 December 2021
- Published by Taylor & Francis in Virulence
- Vol. 13 (1) , 30-45
Open AccessABO blood group is involved in the quality of the specific immune response anti-SARS-CoV-2
Since December 2019, the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread throughout the world. To eradicate it, it is crucial to acquire a strong and long-lasting anti-SARS-CoV-2 immunity, by either natural infection or vaccination. We collected blood samples 12–305 days after positive polymerase chain reactions (PCRs) from 35 recovered individuals infected by SARS-CoV-2. Peripheral blood mononuclear cells were stimulated with SARS-CoV-2-derived peptide pools, such as the spike (S), nucleocapsid (N) and membrane (M) proteins, and we quantified anti-S immunoglobulins in plasma. After 10 months post-infection, we observed a sustained SARS-CoV-2-specific CD4+ T-cell response directed against M-protein, but responses against S- or N-proteins were lost over time. Besides, we demonstrated that O-group individuals presented significantly lower frequencies of specific CD4+ T-cell responses against Pep-M than non O-group individuals. The non O-group subjects also needed longer to clear the virus, and they lost cellular immune responses over time, compared to the O-group individuals, who showed a persistent specific immune response against SARS-CoV-2. Therefore, the S-specific immune response was lost over time, and individual factors might determine the sustainability of the body’s defenses, which must be considered in the future design of vaccines to achieve continuous anti-SARS-CoV-2 immunity.
- 1 September 2021
- Published by Elsevier in Transplantation Proceedings
- Vol. 53 (7) , 2377-2381
Human Leukocyte Antigen Antibody Sampling in Ventricular Assist Device Recipients: Are We Talking?
- 1 September 2021
- Published by Elsevier in Transplantation Proceedings
- Vol. 53 (7) , 2377-2381
Human Leukocyte Antigen Antibody Sampling in Ventricular Assist Device Recipients: Are We Talking?
- Open Access
- 8 June 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (11) , 3649-3662
Characterization of ABH-subtype donor-specific antibodies in ABO-A-incompatible kidney transplantation
- 8 June 2021
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (11) , 3649-3662
Open AccessCharacterization of ABH-subtype donor-specific antibodies in ABO-A-incompatible kidney transplantation
- Open Access
- 1 April 2021
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 40 (4) , S229
ABO-Incompatible Heart Transplantation in Older Children Using Immune Modulation
- 1 April 2021
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 40 (4) , S229
Open AccessABO-Incompatible Heart Transplantation in Older Children Using Immune Modulation